Cynosure Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cynosure Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,478	Closed	-$427K	–	107
2018 Q2	$427K	Buy	+2,478	New	+$405K	0.12%	128

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Cynosure Advisors's JAZZ Position: Q3 2018 in Review

Cynosure Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2018, closing a stake of 2,478 shares — an estimated $427K sold.

Cynosure Advisors first reported a position in JAZZ in Q2 2018 and held it in 1 quarter. The position peaked at $427K in Q2 2018. 403 funds tracked by Wall St. Rank hold JAZZ as of Q3 2018.

Cynosure Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Cynosure Advisors sold 2,478 Jazz Pharmaceuticals shares in Q3 2018, an estimated $427K.
Cynosure Advisors first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Cynosure Advisors's Jazz Pharmaceuticals position peaked at $427K in Q2 2018.
403 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.